Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up by as much as ...

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

Contrave and Wegovy are both weight loss medications. Learn about their effectiveness, side effects, costs, and which ...

As semaglutide-based weight loss treatments, such as Ozempic and Wegovy, become more popular, new side effects are emerging - ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

Eli Lilly ( NYSE: LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Affordable and alternative versions of popular weigh loss drugs, like Ozempic and Wegovy, may no longer be available.

Thalia LeBlanc's tried-and-true methods to stay fit started failing. Taking compounded tirzepatide has turned things around.

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...